Drug Trial Radar · NCT04677426
129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
Last checked: Nov 20, 2026Latest source record: Sep 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 1, 2022
Primary completion
Aug 1, 2022
Study completion Aug 1, 2022
Sponsor
- Lead sponsor
- University of Kansas Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Duke University; Children's Hospital Medical Center, Cincinnati; Boehringer Ingelheim
- First posted
- Dec 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research is a study to test the reliability of Hyperpolarized Xenon MRI (HXe MRI) as a biomarker in interstitial lung disease. The study is a non-randomized study to evaluate the test-retest performance of HXe MRI in Idiopathic Pulmonary Fibrosis (IPF) and chronic Hypersensitivity Pneumonitis (cHP) as a non-invasive biomarker of disease severity and prognosis. The study will include approximately 15 subjects with IPF, 15 subjects with cHP and 10 sex and age-matched normal controls performed across 3 sites.
Conditions
- Idiopathic Pulmonary Fibrosis
- Hypersensitivity Pneumonitis
Interventions
Hyperpolarized Xe129Drug
Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RBC:Barrier RatioTime frame: RBC:Barrier will be assessed at Baseline and at 6 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.